Lung adenocarcinoma study published by CPTAC
In a study published in the journal Cell in July this year, members of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) from MCTP and, UM collaborators, teamed with other investigators in an international effort, to characterize the proteogenomic profiles of lung adenocarcinoma. This investigation led to a comprehensive proteogenomic characterization of 110 lung adenocarcinomas and 101 matched normal adjacent tissues (NATs) incorporating genomics, epigenomics, deep-scale proteomics, phosphoproteomics, and acetylproteomics. Multi-omics clustering revealed four subgroups defined by key driver mutations, country, and gender. Proteomic and phosphoproteomic data illuminated biology downstream of copy number aberrations, somatic mutations, and fusions and identified therapeutic vulnerabilities associated with driver events involving KRAS, EGFR, and ALK. Smoking-associated LUADs showed correlation with other environmental exposure signatures and a field effect in NATs. Matched NATs allowed identification of differentially expressed proteins with potential diagnostic and therapeutic utility. This proteogenomics dataset represents a unique public resource for researchers and clinicians seeking to better understand and treat lung adenocarcinomas. The study was published in Cell.
UM Authors: Saravana M. Dhanasekaran, Rahul Mannan, Pankaj Vats, Chandan Kumar-Sinha, Felipe da Veiga Leprevost, Gilbert S. Omenn, Marcin P. Cieslik, Alexey I. Nesvizhskii and Arul M. Chinnaiyan
Additional Authors from MCTP: Rohit Mehra, Seema Chugh, Sunita Shankar
Read NCI press release